Pakistan · Delayed Price · Currency is PKR Citi Pharma Statistics
Total Valuation
Citi Pharma has a market cap or net worth of PKR 20.84 billion. The enterprise value is 22.20 billion.
| Market Cap | 20.84B |
| Enterprise Value | 22.20B |
Important Dates
The last earnings date was Tuesday, October 7, 2025.
| Earnings Date | Oct 7, 2025 |
| Ex-Dividend Date | Oct 17, 2025 |
Share Statistics
Citi Pharma has 228.46 million shares outstanding.
| Current Share Class | 228.46M |
| Shares Outstanding | 228.46M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.62% |
| Owned by Insiders (%) | 52.11% |
| Owned by Institutions (%) | 11.57% |
| Float | 101.56M |
Valuation Ratios
The trailing PE ratio is 23.39 and the forward PE ratio is 14.48.
| PE Ratio | 23.39 |
| Forward PE | 14.48 |
| PS Ratio | 1.58 |
| PB Ratio | 1.92 |
| P/TBV Ratio | 1.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.53, with an EV/FCF ratio of -47.16.
| EV / Earnings | 24.89 |
| EV / Sales | 1.69 |
| EV / EBITDA | 12.53 |
| EV / EBIT | 13.84 |
| EV / FCF | -47.16 |
Financial Position
The company has a current ratio of 1.30, with a Debt / Equity ratio of 0.27.
| Current Ratio | 1.30 |
| Quick Ratio | 0.66 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | 1.66 |
| Debt / FCF | -6.27 |
| Interest Coverage | 5.05 |
Financial Efficiency
Return on equity (ROE) is 10.81% and return on invested capital (ROIC) is 9.59%.
| Return on Equity (ROE) | 10.81% |
| Return on Assets (ROA) | 6.71% |
| Return on Invested Capital (ROIC) | 9.59% |
| Return on Capital Employed (ROCE) | 14.41% |
| Revenue Per Employee | 24.77M |
| Profits Per Employee | 1.68M |
| Employee Count | 531 |
| Asset Turnover | 0.88 |
| Inventory Turnover | 3.12 |
Taxes
In the past 12 months, Citi Pharma has paid 462.47 million in taxes.
| Income Tax | 462.47M |
| Effective Tax Rate | 34.14% |
Stock Price Statistics
The stock price has increased by +132.17% in the last 52 weeks. The beta is 0.56, so Citi Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | +132.17% |
| 50-Day Moving Average | 94.43 |
| 200-Day Moving Average | 88.75 |
| Relative Strength Index (RSI) | 43.92 |
| Average Volume (20 Days) | 5,010,316 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Citi Pharma had revenue of PKR 13.15 billion and earned 892.04 million in profits. Earnings per share was 3.90.
| Revenue | 13.15B |
| Gross Profit | 2.02B |
| Operating Income | 1.60B |
| Pretax Income | 1.35B |
| Net Income | 892.04M |
| EBITDA | 1.77B |
| EBIT | 1.60B |
| Earnings Per Share (EPS) | 3.90 |
Balance Sheet
The company has 1.59 billion in cash and 2.95 billion in debt, giving a net cash position of -1.36 billion or -5.95 per share.
| Cash & Cash Equivalents | 1.59B |
| Total Debt | 2.95B |
| Net Cash | -1.36B |
| Net Cash Per Share | -5.95 |
| Equity (Book Value) | 10.87B |
| Book Value Per Share | 47.57 |
| Working Capital | 2.17B |
Cash Flow
In the last 12 months, operating cash flow was -320.70 million and capital expenditures -150.06 million, giving a free cash flow of -470.77 million.
| Operating Cash Flow | -320.70M |
| Capital Expenditures | -150.06M |
| Free Cash Flow | -470.77M |
| FCF Per Share | -2.06 |
Margins
Gross margin is 15.34%, with operating and profit margins of 12.20% and 6.78%.
| Gross Margin | 15.34% |
| Operating Margin | 12.20% |
| Pretax Margin | 10.30% |
| Profit Margin | 6.78% |
| EBITDA Margin | 13.43% |
| EBIT Margin | 12.20% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 3.50, which amounts to a dividend yield of 3.86%.
| Dividend Per Share | 3.50 |
| Dividend Yield | 3.86% |
| Dividend Growth (YoY) | 7.69% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 82.94% |
| Buyback Yield | n/a |
| Shareholder Yield | 3.86% |
| Earnings Yield | 4.28% |
| FCF Yield | -2.26% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on October 18, 2021. It was a forward split with a ratio of 1.1.
| Last Split Date | Oct 18, 2021 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
Citi Pharma has an Altman Z-Score of 2.43 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.43 |
| Piotroski F-Score | 3 |